Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 16, 2026

Deals Roundup: J&J Buys Ollin, Lilly Adds Calytrix, and Novartis and Sanofi Strike Platform Pacts

Listen
0:00 / 0:00

Key Takeaways

  • Johnson & Johnson adds OLN324, a ~41 kDa VEGF/Ang2 bispecific, after phase 1b JADE showed 12-week retreatment freedom comparable to faricimab, positioning for longer durability in wet AMD/DME.
  • Blackstone’s $750 million multi-year co-funding shifts late-stage ophthalmology development risk off J&J’s balance sheet in exchange for milestones and single-digit royalties.
SHOW MORE

J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront, leading a set of deals announced in recent days that span ophthalmology, rare blood cancers, antibody-drug conjugate (ADC) technology, and nonviral DNA medicines.¹ Eli Lilly agreed to buy Calytrix Bio for up to $1.5 billion, Novartis licensed OBI Pharma’s ADC conjugation platform, and Seawolf Therapeutics emerged from stealth with $100 million and a Sanofi partnership worth up to $1.2 billion.²˒³˒⁴

“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments.” Kip Connor, vice president, ophthalmology disease area stronghold leader, Johnson & Johnson

What is J&J getting in Ollin?

J&J will acquire Ollin, a clinical-stage company developing therapies for serious eye diseases, for $2.2 billion upfront plus potential regulatory and commercial milestones of up to approximately $1.125 billion.¹ The deal adds OLN324, a phase 3 bispecific antibody that targets vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2) in a small protein format, for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).¹ The transaction is expected to close before the end of 2026.¹

OLN324 was discovered by Innovent Biologics, which developed it with Ollin under the code IBI324.⁵ In the head-to-head Phase 1b JADE study against Roche’s VEGF/Ang2 bispecific Vabysmo (faricimab), 82% of patients receiving OLN324 4 mg went 12 weeks without retreatment, compared with 81% of patients receiving faricimab.⁵ The antibody is about 41 kDa and was designed with higher potency and a higher molar dose than faricimab.⁶

“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments,” said Kip Connor, vice president, ophthalmology disease area stronghold leader at J&J.¹

Separately, Blackstone Life Sciences will pay J&J $750 million over multiple years to fully fund OLN324’s phase 3 program, in exchange for regulatory and sales milestones and single-digit royalties.¹ It is Blackstone’s second large pharma co-funding deal in a week, following its agreement to provide Pfizer up to $1.5 billion for the monthly GLP-1 berobenatide.

Why is Lilly buying Calytrix?

Lilly agreed to acquire Calytrix Bio, a privately held developer of therapies for myeloproliferative neoplasms (MPNs), for up to $1.5 billion in cash, including an undisclosed upfront payment and clinical and regulatory milestones.² The deal is Lilly’s 14th acquisition of 2026.⁷

Calytrix’s lead asset is a preclinical biparatopic antibody designed to target both Type 1 and Type 2 mutant calreticulin (mCALR) in essential thrombocythemia (ET) and myelofibrosis.² The company describes mutant CALR as a tumor-specific cell-surface target that could allow a drug to deplete the disease-driving mutant clone while sparing healthy blood cell production.²

“From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF,” said Brad Prosek, president and chief executive officer of Calytrix Bio.² Interest in disease-modifying MPN antibodies is growing, as BioPharm International® reported when Alethio Therapeutics raised $90 million earlier this month for its G6B antibody and a mutant CALR program.

What does Novartis gain from OBI?

Novartis entered a collaboration and license agreement with Taiwan-based OBI Pharma to develop next-generation ADCs with novel payloads using OBI’s platform technologies.³ Novartis gains exclusive worldwide rights to OBI’s related patents and know-how for selected, undisclosed Novartis payload classes, with an option to add more.³ OBI will receive $30 million upfront and is eligible for milestones bringing the total potential deal value above $2 billion, plus tiered royalties.³

OBI’s GlycOBI technology is a glycan-based conjugation approach designed to work with a range of antibodies, linkers, and payloads, and its GlycOBI DUO extension enables dual-payload ADCs.³ “This collaboration supports our ambition to innovate novel therapies,” said Shiva Malek, global head of oncology, biomedical research at Novartis.³

What is Seawolf developing?

San Diego-based Seawolf Therapeutics emerged from stealth with $100 million in seed and Series A funding from investors including Versant Ventures, MPM BioImpact, Novartis Venture Fund, Eli Lilly and Company, and CRISPR Therapeutics.⁴ The company also signed a multi-target research collaboration and exclusive license agreement with Sanofi to develop therapies for bleeding disorders and other undisclosed indications, with up to $1.2 billion in milestones plus tiered royalties.⁴

Seawolf’s TRIDENT platform uses lipid nanoparticles to deliver DNA that encodes a therapeutic protein, along with a factor that helps the DNA enter the cell nucleus.⁴ The company says the approach can produce longer-lasting protein expression than RNA-based LNP therapies and, unlike viral gene therapies, can be redosed.⁴ Its lead proprietary program, for metabolic diseases, is advancing toward development candidate selection.⁴

What do the deals signal?

Recent acquisitions and licensing deals return capital to the broader biotech market. In a BioPharm International video interview, Sara Jane Demy, chief executive officer of Demy-Colton, said, “Every time a company makes a move like that, or there is an acquisition, it frees up capital,” adding that it “puts more capital back into the space, and enables more research and development to be done.”

References

  1. Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology. News release. Johnson & Johnson; November 16, 2026. Accessed November 16, 2026.
  2. Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis. News release. Calytrix Bio; November 16, 2026. Accessed November 16, 2026.
  3. OBI Pharma signs collaboration and license agreement with Novartis. News release. OBI Pharma; November 16, 2026. Accessed November 16, 2026.
  4. Seawolf Therapeutics debuts with $100 million to advance DNA-based therapeutics. News release. Seawolf Therapeutics; November 16, 2026. Accessed November 16, 2026.
  5. Innovent’s partner Ollin Biosciences announces final data from randomized head-to-head study of IBI324 compared to faricimab (Vabysmo) in wet age-related macular degeneration and diabetic macular edema. News release. Innovent Biologics; March 31, 2026. Accessed November 16, 2026.
  6. Malhotra V, Ehrlich JS, Liu W, et al. IBI324/OLN324: A clinical-stage, small-format, higher-potency, high molar dose bispecific VEGF/Ang-2 inhibitor. Invest. Ophthalmol. Vis. Sci. 2025;66(8):5970. ARVO Annual Meeting abstract. June 2025. Accessed November 16, 2026.
  7. LaHucik K. Lilly’s 14th acquisition of the year is a little-known blood cancer biotech. Endpoints News. Published November 16, 2026. Accessed November 16, 2026.

Related to this article